Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
February 25, 2021 7:00 AM ESTStrengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer
Appointed Meeta Chatterjee, Ph.D., to Board of Directors
Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10
Initiated Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease
Ended 2020 with strong cash position of $512 million, and raised additional $250 million in early 2021
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine,... More
